Literature DB >> 2494454

Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.

H D White1, J T Rivers, A H Maslowski, J A Ormiston, M Takayama, H H Hart, D N Sharpe, R M Whitlock, R M Norris.   

Abstract

In a double-blind trial comparing two thrombolytic agents as treatment for acute myocardial infarction, we randomized 270 consecutive patients an average (+/- SD) of 2.5 +/- 0.6 hours after the onset of chest pain from a first myocardial infarction--135 to receive intravenous streptokinase (1.5 million units over 30 minutes) and 135 to receive intravenous recombinant tissue plasminogen activator (rt-PA) (100 mg over three hours). The primary end point was left ventricular function as assessed by cineangiography performed three weeks after infarction. The effects of the two agents on left ventricular function were similar. The ejection fraction was identical (58 +/- 12 percent) in both groups. The end-systolic volume was 61 +/- 29 ml in the streptokinase group and 66 +/- 31 ml in the rt-PA group (P not significant). Patency rates at three weeks for the infarct-related artery were also similar (75 percent in the streptokinase group and 76 percent in the rt-PA group). Reinfarction rates at 30 days were the same (5 percent) in both groups. One patient had a fatal intracerebral hemorrhage 13 hours after receiving rt-PA, and another had a fatal cerebellar hemorrhage 21 hours after receiving rt-PA for reinfarction nine days after treatment with streptokinase. An intention-to-treat analysis revealed that mortality at 30 days was 3.7 percent in the rt-PA group as compared with 7.4 percent in the streptokinase group (P greater than 0.2). Follow-up for a mean of 9.0 months revealed no significant difference in survival; we observed 12 deaths (8.9 percent) in the streptokinase group and 8 deaths (5.9 percent) in the rt-PA group (P = 0.34). We conclude that rt-PA and streptokinase, in the doses given, have similar effects on left ventricular function after a first myocardial infarction. Because of the small number of deaths, it is not possible to determine whether their effects on mortality are similar.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2494454     DOI: 10.1056/NEJM198903303201301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  20 in total

1.  Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.

Authors:  S Sherry
Journal:  Tex Heart Inst J       Date:  1991

2.  Current status of thrombolytic therapy in acute myocardial infarction.

Authors:  B Stein; R Roberts
Journal:  Tex Heart Inst J       Date:  1991

Review 3.  Cardiology.

Authors:  L D Smith; D J Coltart
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

4.  Therapeutic interchange as a cost-containment measure {editorial}.

Authors:  L E Achusim
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

5.  Thrombolytic treatment for recurrent myocardial infarction.

Authors:  H White
Journal:  BMJ       Date:  1991-02-23

6.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

7.  Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 8.  Recent advances in cardiology.

Authors:  C F Shakespeare; D J Coltart
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

Review 9.  Therapeutic options in treating acute myocardial infarction.

Authors:  J W Danforth
Journal:  West J Med       Date:  1989-10

Review 10.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.